gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Vascular endothelial growth factor B

VEGF-B, Vascular Endothelial Growth Factor B, VRF
This gene encodes a member of the PDGF (platelet-derived growth factor)/VEGF (vascular endothelial growth factor) family. The VEGF family members regulate the formation of blood vessels and are involved in endothelial cell physiology. This member is a ligand for VEGFR-1 (vascular endothelial growth factor receptor 1) and NRP-1 (neuropilin-1). Studies in mice showed that this gene was co-expressed with nuclear-encoded mitochondrial genes and the encoded protein specifically controlled endothelial uptake of fatty acids. Alternatively spliced transcript variants encoding distinct isoforms have been identified. [provided by RefSeq, Sep 2011] (from NCBI)
Top mentioned proteins: vascular endothelial growth factor, KDR, VEGF-C, Flt-1, PlGF
Papers using VEGF-B antibodies
Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly
Ganjoo Kristen et al., In Case Reports in Oncology, 2002
... (A-20) polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., USA; unit # sc-152), goat anti-human VEGFB (N-19) polyclonal antibody (Santa Cruz Biotechnology, Inc.; unit # sc-1878), goat ...
Improvement in islet yield from a cold-preserved pancreas by pancreatic ductal collagenase distention at the time of harvesting.
Gelovani Juri G., In PLoS ONE, 1990
... Double-transgenic RIP1-Tag2; RIP1-VEGFB mice were obtained by crossing the single-transgenic RIP1-VEGFB mice with RIP1-Tag2 ...
Papers on VEGF-B
Response to anti-VEGF-A treatment of endothelial cells in vitro.
Nicolò et al., Genova, Italy. In Exp Eye Res, Feb 2016
Cell viability and then expression and secretion of VEGF-A, VEGF-B, VEGF-C and PlGF were evaluated respectively by Real Time-PCR and ELISA.
Anti-inflammatory and lymphangiogenetic effects of low-level laser therapy on lymphedema in an experimental mouse tail model.
Jeon et al., Inch'ŏn, South Korea. In Lasers Med Sci, Jan 2016
Quantitative real-time polymerase chain reaction (qPCR) was performed to measure messenger RNA (mRNA) expression of vascular endothelial growth factor A, B, C, R1, R2, and R3 (VEGF-A, VEGF-B, VEGF-C, VEGFR1, VEGFR2, and VEGFR3) at 12 days post-procedure.
Methylation patterns of Vegfb promoter are associated with gene and protein expression levels: the effects of dietary fatty acids.
García-Escobar et al., Málaga, Spain. In Eur J Nutr, Jan 2016
PURPOSE: We have investigated the epigenetic regulation by dietary fatty acids of Vegfb levels in rats' white adipose tissue and 3T3-L1 cells.
Bevacizumab and Aflibercept Activate Platelets via FcγRIIa.
Yanagi et al., Tokyo, Japan. In Invest Ophthalmol Vis Sci, Jan 2016
In aggregation study, no detectable aggregation was observed in the presence of ranibizumab, while significant aggregation was observed in the presence of VEGF-A and bevacizumab in five cases (one AMD patient and four healthy volunteers), VEGF-B and aflibercept in two cases (two volunteers), and placental growth factor (PlGF) and aflibercept in one case (one volunteer).
Aflibercept a new target therapy in cancer treatment: a review.
Fabozzi et al., Milano, Italy. In Crit Rev Oncol Hematol, Dec 2015
Aflibercept is a recombinant fusion protein of the VEGF receptor (VEGFR)1 and VEGFR2 extracellular domains that binds to VEGF-A, VEGF-B, placental growth factor (PlGF) 1 and 2. Aflibercept has demonstrated preclinical efficacy in different tumor types and exerts its antiangiogenic effects through regression of tumor vasculature, remolding of vasculature, and inhibition of new tumor vessel growth.
Treatment of Exudative Age-related Macular Degeneration: Focus on Aflibercept.
Reiter et al., Pamplona, Spain. In Drugs Aging, Oct 2015
In addition to binding all VEGF-A isoforms, aflibercept also blocks other proangiogenic factors such as VEGF-B and placental growth factor.
Effects of vascular endothelial growth factor-b on the bioelectric activity of rat atrial myocardium under normal conditions and during gradual stretching.
Mladenov et al., Moscow, Russia. In J Biol Regul Homeost Agents, Oct 2015
Using a microelectrode technique we studied the effects of vascular endothelial growth factor-B on the activity of rat atrial myocardium under normal conditions and after gradual stretching of the tissue.
Aflibercept: A Review in Metastatic Colorectal Cancer.
McKeage et al., Auckland, New Zealand. In Drugs, Aug 2015
It binds to all isoforms of VEGF-A as well as VEGF-B and placental growth factor, and, thus, prevents them from binding to and activating their cognate receptors.
VEGF Expression in Pancreatic Cancer and Other Malignancies: A Review of the Literature.
Săftoiu et al., In Rom J Intern Med, Jul 2015
VEGF protein family currently comprises several members: VEGF (or VEGF-A), VEGF-B, VEGF-C and VEGF-D, VEGF-F, placental growth factor (PlGF), and their receptors VEGFR-1, VEGFR-2 and VEGFR-3.
A Functional Role for VEGFR1 Expressed in Peripheral Sensory Neurons in Cancer Pain.
Kuner et al., Heidelberg, Germany. In Cancer Cell, Jul 2015
Tumor-derived VEGF-A, PLGF-2, and VEGF-B augment pain sensitivity through selective activation of VEGF receptor 1 (VEGFR1) expressed in sensory neurons in human cancer and mouse models.
Vascular endothelial growth factor-B in physiology and disease.
Alitalo et al., Helsinki, Finland. In Physiol Rev, 2014
Vascular endothelial growth factor-B (VEGF-B), discovered over 15 years ago, has long been seen as one of the more ambiguous members of the VEGF family.
The role of angiogenic factors in endometrial cancer.
Stetkiewicz et al., Łódź, Poland. In Prz Menopauzalny, 2014
The VEGF family consists of VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F and PLGF (placental growth factor).
Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes.
Eriksson et al., Stockholm, Sweden. In Nature, 2012
Recently it was found that vascular endothelial growth factor B (VEGF-B) controls endothelial uptake and transport of fatty acids in heart and skeletal muscle.
WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing.
Ladomery et al., Bristol, United Kingdom. In Cancer Cell, 2012
In WT1 mutant cells, reduced VEGF(165)b was due to lack of WT1-mediated transcriptional repression of the splicing-factor kinase SRPK1
Promoting effects of carminic acid-enriched cochineal extracts on capsular invasive thyroid carcinomas through targeting activation of angiogenesis in rats.
Shibutani et al., Tokyo, Japan. In J Toxicol Sci, 2011
Transcript level of angiogenesis-related genes, Vegfb and its transcription factor gene, Hif1a, those being downstream of phosphatase and tensin homolog (PTEN)/Akt signaling, were up-regulated in the thyroid tissue with Cochineal extracts administration.
Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis.
Matucci-Cerinic et al., Florence, Italy. In Circ Res, 2011
In systemic sclerosis, a switch from proangiogenic to antiangiogenic VEGF isoforms may have a crucial role in the insufficient angiogenic response to chronic ischemia.
Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons.
Lambrechts et al., Leuven, Belgium. In Faseb J, 2011
Study indicates that VEGF-B, instead of acting as an angiogenic factor, exerts direct neuroprotective effects through FLT1.
Placenta growth factor and vascular endothelial growth factor B expression in the hypoxic lung.
McLoughlin et al., Dublin, Ireland. In Respir Res, 2010
VEGFB and PlGF can either inhibit or potentiate the actions of VEGFA, depending on their relative concentrations, which change in the hypoxic lung.
Vascular endothelial growth factor B controls endothelial fatty acid uptake.
Eriksson et al., Stockholm, Sweden. In Nature, 2010
VEGF-B specifically controlled endothelial uptake of fatty acids via transcriptional regulation of vascular fatty acid transport proteins
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Carmeliet et al., Berlin, Germany. In Nat Rev Cancer, 2008
Less than 5 years ago, it was still not clear whether anti-angiogenic drugs would prove successful in the clinic.
share on facebooktweetadd +1mail to friends